Report cover image

Neurology Contract Research Organization

Published Jul 01, 2025
Length 497 Pages
SKU # GJOB20171964

Description

Global Neurology Contract Research Organization Market to Reach US$11.7 Billion by 2030

The global market for Neurology Contract Research Organization estimated at US$8.2 Billion in the year 2024, is expected to reach US$11.7 Billion by 2030, growing at a CAGR of 6.0% over the analysis period 2024-2030. Clinical Services, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$3.5 Billion by the end of the analysis period. Growth in the Data Management Services segment is estimated at 6.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.2 Billion While China is Forecast to Grow at 9.7% CAGR

The Neurology Contract Research Organization market in the U.S. is estimated at US$2.2 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.4 Billion by the year 2030 trailing a CAGR of 9.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 6.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.0% CAGR.

Global Neurology Contract Research Organization (CRO) Market - Key Trends & Drivers Summarized

Why Are Neurology-Focused CROs Becoming Indispensable in Drug Development?

Neurology-focused Contract Research Organizations (CROs) play a vital role in supporting pharmaceutical and biotechnology companies throughout the drug development lifecycle for central nervous system (CNS) disorders. These CROs bring specialized capabilities in conducting preclinical and clinical trials tailored to complex neurological conditions, such as Alzheimer’s, Parkinson’s, multiple sclerosis, epilepsy, and rare neuromuscular diseases. Given the high failure rate and extended timelines of neurology drug development, outsourcing to CROs helps streamline processes, reduce costs, and improve trial design precision.

Neurology CROs offer access to experienced clinical investigators, patient recruitment networks, neuroimaging expertise, and regulatory strategy tailored to CNS drug pathways. Their involvement is particularly crucial in early-phase trials where disease heterogeneity, placebo response, and slow progression complicate endpoint measurement. By handling protocol design, data management, and neuro-specific biomarkers, these organizations allow sponsors to focus on core research while ensuring compliance with regional and global standards.

How Are Technological Integrations Enhancing Neurology CRO Capabilities?

Digital transformation has significantly improved the operational efficiency and analytical strength of neurology CROs. Advanced neuroimaging platforms, machine learning-based cognitive assessment tools, and wearable neuro-monitoring devices are increasingly embedded into study protocols. These tools help collect more granular and real-time data on patient behavior, symptom patterns, and treatment response. Remote monitoring technologies also enhance retention in long-duration trials, which are common in neurodegenerative disease research.

Artificial intelligence and predictive analytics are being used to identify optimal trial sites, forecast recruitment timelines, and analyze diverse data sets from electronic health records, brain scans, and biospecimens. Integration of electronic data capture systems with centralized monitoring allows neurology CROs to support decentralized or hybrid trial models, expanding access to participants in different geographies. These digital capabilities are essential for complex trial designs, such as adaptive trials and those requiring rare disease cohorts.

What Factors Are Driving Sponsors to Outsource More Neurology Trials?

Outsourcing in neurology is increasing due to several scientific and operational challenges that sponsors face. High variability in disease progression, lack of validated biomarkers, and evolving regulatory expectations make in-house management of neurology trials resource-intensive. CROs provide end-to-end support from preclinical modeling and IND-enabling studies to site selection, patient registry development, and post-marketing surveillance. Their ability to offer multidisciplinary teams with expertise in neurology, biostatistics, imaging, and pharmacovigilance adds value across the study lifecycle.

Globalization of trials has also contributed to the growing demand for CRO services in neurology. Conducting studies across multiple countries ensures diverse patient representation and access to larger participant pools, especially for rare CNS disorders. CROs with global infrastructure and therapeutic alignment are preferred partners for managing such trials, navigating local regulatory landscapes, and ensuring standardized data across regions. Mergers, partnerships, and platform expansions among CROs are further reshaping competition and capabilities in this space.

Growth in the neurology contract research organization market is driven by several factors.

Rising investment in neurological drug discovery, especially in Alzheimer’s, ALS, and multiple sclerosis, is fueling demand for specialized CROs with proven CNS expertise. Increasing complexity of clinical trial protocols, growing regulatory scrutiny, and the need for long-term safety and cognitive function tracking are encouraging sponsors to seek expert external support. Emergence of digital biomarkers, mobile health tools, and decentralized trial formats is prompting CROs to offer more integrated and technologically enabled solutions. Expanding prevalence of neurological disorders and the push for faster drug development timelines have created sustained demand for efficient, experienced, and globally networked CROs. Collaborative efforts between pharmaceutical firms and neurology CROs are also accelerating innovation and expanding the scope of CNS research worldwide.

SCOPE OF STUDY:

The report analyzes the Neurology Contract Research Organization market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Service (Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology, Quality & Compliance); Study (Neuroscience Focused Study, Neurology Focused Study); Indication (Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication, Other Indications); End-Use (Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use, Academic & Research Institutes End-Use)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -
  • Alimentiv Inc.
  • Axon CRO
  • Atlantic Research Group, Inc.
  • Charles River Laboratories
  • CTI Clinical Trial & Consulting
  • EphyX Neuroscience
  • Ergomed plc
  • Fortrea Holdings Inc. (formerly Covance/Labcorp Drug Development)
  • ICON plc
  • IQVIA Inc.
  • Labcorp Drug Development
  • MD Biosciences
  • Medpace Holdings, Inc.
  • Neuroservices-Alliance
  • Neuron Experts
  • Parexel International Corporation
  • Pharmaron Beijing Co., Ltd.
  • PPD Inc. (Thermo Fisher Scientific)
  • QPS Neuropharmacology
  • Syneos Health
  • WuXi AppTec
AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

Table of Contents

497 Pages
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Tariff Impact on Global Supply Chain Patterns
Neurology Contract Research Organization – Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Outsourcing of Neurology Trials Drives Growth for Specialized CRO Services
Increasing Complexity of CNS Drug Development Strengthens Business Case for Neurology-Focused CROs
Growing Demand for Rare and Orphan Neurological Disorder Studies Expands Niche CRO Opportunities
Shift Toward Decentralized Clinical Trials Spurs Adoption of Tech-Enabled Neurology CRO Models
High Failure Rates in CNS Drug Trials Drive Reliance on Specialized Clinical Expertise
Use of AI and Digital Biomarkers in Trial Design Accelerates Innovation in Neurology CROs
Pharmaceutical and Biotech Companies Increasingly Leverage CROs for Global Neurology Trials
Emergence of Novel Neuromodulation Therapies Generates Demand for Customized CRO Support
Rising Focus on Early-Phase CNS Trials Expands Scope for Preclinical Neurology CRO Services
Demand for Biomarker-Driven CNS Studies Propels Integration of Imaging and Molecular CRO Capabilities
Increasing Regulatory Scrutiny on Neurology Trials Enhances Demand for Experienced CRO Partners
Patient Recruitment and Retention Challenges in CNS Studies Drive Use of Patient-Centric CRO Strategies
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Neurology Contract Research Organization Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for Neurology Contract Research Organization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 4: World 16-Year Perspective for Neurology Contract Research Organization by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Clinical Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 6: World Historic Review for Clinical Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 7: World 16-Year Perspective for Clinical Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Data Management Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 9: World Historic Review for Data Management Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 10: World 16-Year Perspective for Data Management Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Drug Safety by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 12: World Historic Review for Drug Safety by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 13: World 16-Year Perspective for Drug Safety by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Medical & Scientific Writing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 15: World Historic Review for Medical & Scientific Writing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 16: World 16-Year Perspective for Medical & Scientific Writing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Regulatory Affairs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 18: World Historic Review for Regulatory Affairs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 19: World 16-Year Perspective for Regulatory Affairs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Pharmacology & Toxicology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 21: World Historic Review for Pharmacology & Toxicology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 22: World 16-Year Perspective for Pharmacology & Toxicology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Quality & Compliance by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 24: World Historic Review for Quality & Compliance by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 25: World 16-Year Perspective for Quality & Compliance by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Alzheimer`s Disease Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 27: World Historic Review for Alzheimer`s Disease Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 28: World 16-Year Perspective for Alzheimer`s Disease Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 29: World Recent Past, Current & Future Analysis for Brain Tumor Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 30: World Historic Review for Brain Tumor Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 31: World 16-Year Perspective for Brain Tumor Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 32: World Recent Past, Current & Future Analysis for Epilepsy & Seizures Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 33: World Historic Review for Epilepsy & Seizures Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 34: World 16-Year Perspective for Epilepsy & Seizures Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 35: World Recent Past, Current & Future Analysis for Schizophrenia Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 36: World Historic Review for Schizophrenia Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 37: World 16-Year Perspective for Schizophrenia Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 38: World Recent Past, Current & Future Analysis for Multiple Sclerosis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 39: World Historic Review for Multiple Sclerosis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 40: World 16-Year Perspective for Multiple Sclerosis Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 41: World Recent Past, Current & Future Analysis for Muscular Dystrophy Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 42: World Historic Review for Muscular Dystrophy Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 43: World 16-Year Perspective for Muscular Dystrophy Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 44: World Recent Past, Current & Future Analysis for Stroke Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 45: World Historic Review for Stroke Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 46: World 16-Year Perspective for Stroke Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 47: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 48: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 49: World 16-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 50: World Recent Past, Current & Future Analysis for Pharma & Biopharma Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 51: World Historic Review for Pharma & Biopharma Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 52: World 16-Year Perspective for Pharma & Biopharma Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 53: World Recent Past, Current & Future Analysis for Medical Device Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 54: World Historic Review for Medical Device Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 55: World 16-Year Perspective for Medical Device Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 56: World Recent Past, Current & Future Analysis for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 57: World Historic Review for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 58: World 16-Year Perspective for Academic & Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 59: World Recent Past, Current & Future Analysis for Neuroscience Focused Study by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 60: World Historic Review for Neuroscience Focused Study by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 61: World 16-Year Perspective for Neuroscience Focused Study by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 62: World Recent Past, Current & Future Analysis for Neurology Focused Study by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 63: World Historic Review for Neurology Focused Study by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 64: World 16-Year Perspective for Neurology Focused Study by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Neurology Contract Research Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 65: USA Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 66: USA Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 67: USA 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
TABLE 68: USA Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 69: USA Historic Review for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 70: USA 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 71: USA Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 72: USA Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 73: USA 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
TABLE 74: USA Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 75: USA Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 76: USA 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
CANADA
TABLE 77: Canada Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 78: Canada Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 79: Canada 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
TABLE 80: Canada Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 81: Canada Historic Review for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 82: Canada 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 83: Canada Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 84: Canada Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 85: Canada 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
TABLE 86: Canada Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 87: Canada Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 88: Canada 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
JAPAN
Neurology Contract Research Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 89: Japan Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 90: Japan Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 91: Japan 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
TABLE 92: Japan Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 93: Japan Historic Review for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 94: Japan 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 95: Japan Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 96: Japan Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 97: Japan 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
TABLE 98: Japan Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 99: Japan Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 100: Japan 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
CHINA
Neurology Contract Research Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 101: China Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 102: China Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 103: China 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
TABLE 104: China Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 105: China Historic Review for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 106: China 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 107: China Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 108: China Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 109: China 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
TABLE 110: China Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 111: China Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 112: China 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
EUROPE
Neurology Contract Research Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 113: Europe Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 114: Europe Historic Review for Neurology Contract Research Organization by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 115: Europe 16-Year Perspective for Neurology Contract Research Organization by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
TABLE 116: Europe Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 117: Europe Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 118: Europe 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
TABLE 119: Europe Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 120: Europe Historic Review for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 121: Europe 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 122: Europe Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 123: Europe Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 124: Europe 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
TABLE 125: Europe Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 126: Europe Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 127: Europe 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
FRANCE
Neurology Contract Research Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 128: France Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 129: France Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 130: France 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
TABLE 131: France Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 132: France Historic Review for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 133: France 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 134: France Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 135: France Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 136: France 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
TABLE 137: France Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 138: France Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 139: France 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
GERMANY
Neurology Contract Research Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 140: Germany Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 141: Germany Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 142: Germany 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
TABLE 143: Germany Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 144: Germany Historic Review for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 145: Germany 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 146: Germany Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 147: Germany Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 148: Germany 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
TABLE 149: Germany Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 150: Germany Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 151: Germany 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
ITALY
TABLE 152: Italy Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 153: Italy Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 154: Italy 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
TABLE 155: Italy Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 156: Italy Historic Review for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 157: Italy 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 158: Italy Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 159: Italy Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 160: Italy 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
TABLE 161: Italy Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 162: Italy Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 163: Italy 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
UNITED KINGDOM
Neurology Contract Research Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 164: UK Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 165: UK Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 166: UK 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
TABLE 167: UK Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 168: UK Historic Review for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 169: UK 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 170: UK Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 171: UK Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 172: UK 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
TABLE 173: UK Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 174: UK Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 175: UK 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
SPAIN
TABLE 176: Spain Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 177: Spain Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 178: Spain 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
TABLE 179: Spain Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 180: Spain Historic Review for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 181: Spain 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 182: Spain Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 183: Spain Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 184: Spain 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
TABLE 185: Spain Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 186: Spain Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 187: Spain 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
RUSSIA
TABLE 188: Russia Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 189: Russia Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 190: Russia 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
TABLE 191: Russia Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 192: Russia Historic Review for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 193: Russia 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 194: Russia Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 195: Russia Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 196: Russia 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
TABLE 197: Russia Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 198: Russia Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 199: Russia 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
REST OF EUROPE
TABLE 200: Rest of Europe Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 201: Rest of Europe Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 202: Rest of Europe 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
TABLE 203: Rest of Europe Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 204: Rest of Europe Historic Review for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 205: Rest of Europe 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 206: Rest of Europe Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 207: Rest of Europe Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 208: Rest of Europe 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
TABLE 209: Rest of Europe Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 210: Rest of Europe Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 211: Rest of Europe 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
ASIA-PACIFIC
Neurology Contract Research Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 212: Asia-Pacific Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 213: Asia-Pacific Historic Review for Neurology Contract Research Organization by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 214: Asia-Pacific 16-Year Perspective for Neurology Contract Research Organization by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
TABLE 215: Asia-Pacific Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 216: Asia-Pacific Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 217: Asia-Pacific 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
TABLE 218: Asia-Pacific Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 219: Asia-Pacific Historic Review for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 220: Asia-Pacific 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 221: Asia-Pacific Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 222: Asia-Pacific Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 223: Asia-Pacific 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
TABLE 224: Asia-Pacific Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 225: Asia-Pacific Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 226: Asia-Pacific 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
AUSTRALIA
Neurology Contract Research Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
TABLE 227: Australia Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 228: Australia Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 229: Australia 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
TABLE 230: Australia Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 231: Australia Historic Review for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 232: Australia 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 233: Australia Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 234: Australia Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 235: Australia 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
TABLE 236: Australia Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 237: Australia Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 238: Australia 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
INDIA
Neurology Contract Research Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
TABLE 239: India Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 240: India Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 241: India 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
TABLE 242: India Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 243: India Historic Review for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 244: India 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 245: India Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 246: India Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 247: India 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
TABLE 248: India Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 249: India Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 250: India 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
SOUTH KOREA
TABLE 251: South Korea Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 252: South Korea Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 253: South Korea 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
TABLE 254: South Korea Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 255: South Korea Historic Review for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 256: South Korea 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 257: South Korea Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 258: South Korea Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 259: South Korea 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
TABLE 260: South Korea Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 261: South Korea Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 262: South Korea 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
REST OF ASIA-PACIFIC
TABLE 263: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 264: Rest of Asia-Pacific Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 265: Rest of Asia-Pacific 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
TABLE 266: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 267: Rest of Asia-Pacific Historic Review for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 268: Rest of Asia-Pacific 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 269: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 270: Rest of Asia-Pacific Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 271: Rest of Asia-Pacific 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
TABLE 272: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 273: Rest of Asia-Pacific Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 274: Rest of Asia-Pacific 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
LATIN AMERICA
Neurology Contract Research Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
TABLE 275: Latin America Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 276: Latin America Historic Review for Neurology Contract Research Organization by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 277: Latin America 16-Year Perspective for Neurology Contract Research Organization by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
TABLE 278: Latin America Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 279: Latin America Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 280: Latin America 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
TABLE 281: Latin America Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 282: Latin America Historic Review for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 283: Latin America 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 284: Latin America Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 285: Latin America Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 286: Latin America 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
TABLE 287: Latin America Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 288: Latin America Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 289: Latin America 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
ARGENTINA
TABLE 290: Argentina Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 291: Argentina Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 292: Argentina 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
TABLE 293: Argentina Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 294: Argentina Historic Review for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 295: Argentina 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 296: Argentina Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 297: Argentina Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 298: Argentina 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
TABLE 299: Argentina Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 300: Argentina Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 301: Argentina 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
BRAZIL
TABLE 302: Brazil Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 303: Brazil Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 304: Brazil 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
TABLE 305: Brazil Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 306: Brazil Historic Review for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 307: Brazil 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 308: Brazil Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 309: Brazil Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 310: Brazil 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
TABLE 311: Brazil Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 312: Brazil Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 313: Brazil 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
MEXICO
TABLE 314: Mexico Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 315: Mexico Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 316: Mexico 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
TABLE 317: Mexico Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 318: Mexico Historic Review for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 319: Mexico 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 320: Mexico Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 321: Mexico Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 322: Mexico 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
TABLE 323: Mexico Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 324: Mexico Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 325: Mexico 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
REST OF LATIN AMERICA
TABLE 326: Rest of Latin America Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 327: Rest of Latin America Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 328: Rest of Latin America 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
TABLE 329: Rest of Latin America Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 330: Rest of Latin America Historic Review for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 331: Rest of Latin America 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 332: Rest of Latin America Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 333: Rest of Latin America Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 334: Rest of Latin America 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
TABLE 335: Rest of Latin America Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 336: Rest of Latin America Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 337: Rest of Latin America 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
MIDDLE EAST
Neurology Contract Research Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
TABLE 338: Middle East Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 339: Middle East Historic Review for Neurology Contract Research Organization by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 340: Middle East 16-Year Perspective for Neurology Contract Research Organization by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
TABLE 341: Middle East Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 342: Middle East Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 343: Middle East 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
TABLE 344: Middle East Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 345: Middle East Historic Review for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 346: Middle East 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 347: Middle East Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 348: Middle East Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 349: Middle East 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
TABLE 350: Middle East Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 351: Middle East Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 352: Middle East 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
IRAN
TABLE 353: Iran Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 354: Iran Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 355: Iran 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
TABLE 356: Iran Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 357: Iran Historic Review for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 358: Iran 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 359: Iran Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 360: Iran Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 361: Iran 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
TABLE 362: Iran Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 363: Iran Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 364: Iran 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
ISRAEL
TABLE 365: Israel Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 366: Israel Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 367: Israel 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
TABLE 368: Israel Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 369: Israel Historic Review for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 370: Israel 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 371: Israel Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 372: Israel Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 373: Israel 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
TABLE 374: Israel Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 375: Israel Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 376: Israel 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
SAUDI ARABIA
TABLE 377: Saudi Arabia Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 378: Saudi Arabia Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 379: Saudi Arabia 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
TABLE 380: Saudi Arabia Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 381: Saudi Arabia Historic Review for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 382: Saudi Arabia 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 383: Saudi Arabia Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 384: Saudi Arabia Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 385: Saudi Arabia 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
TABLE 386: Saudi Arabia Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 387: Saudi Arabia Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 388: Saudi Arabia 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
UNITED ARAB EMIRATES
TABLE 389: UAE Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 390: UAE Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 391: UAE 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
TABLE 392: UAE Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 393: UAE Historic Review for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 394: UAE 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 395: UAE Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 396: UAE Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 397: UAE 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
TABLE 398: UAE Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 399: UAE Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 400: UAE 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
REST OF MIDDLE EAST
TABLE 401: Rest of Middle East Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 402: Rest of Middle East Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 403: Rest of Middle East 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
TABLE 404: Rest of Middle East Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 405: Rest of Middle East Historic Review for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 406: Rest of Middle East 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 407: Rest of Middle East Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 408: Rest of Middle East Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 409: Rest of Middle East 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
TABLE 410: Rest of Middle East Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 411: Rest of Middle East Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 412: Rest of Middle East 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
AFRICA
Neurology Contract Research Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
TABLE 413: Africa Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 414: Africa Historic Review for Neurology Contract Research Organization by Service - Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 415: Africa 16-Year Perspective for Neurology Contract Research Organization by Service - Percentage Breakdown of Value Sales for Clinical Services, Data Management Services, Drug Safety, Medical & Scientific Writing, Regulatory Affairs, Pharmacology & Toxicology and Quality & Compliance for the Years 2014, 2025 & 2030
TABLE 416: Africa Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 417: Africa Historic Review for Neurology Contract Research Organization by Indication - Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 418: Africa 16-Year Perspective for Neurology Contract Research Organization by Indication - Percentage Breakdown of Value Sales for Alzheimer`s Disease Indication, Brain Tumor Indication, Epilepsy & Seizures Indication, Schizophrenia Indication, Multiple Sclerosis Indication, Muscular Dystrophy Indication, Stroke Indication and Other Indications for the Years 2014, 2025 & 2030
TABLE 419: Africa Recent Past, Current & Future Analysis for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 420: Africa Historic Review for Neurology Contract Research Organization by End-Use - Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 421: Africa 16-Year Perspective for Neurology Contract Research Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies End-Use, Medical Device Companies End-Use and Academic & Research Institutes End-Use for the Years 2014, 2025 & 2030
TABLE 422: Africa Recent Past, Current & Future Analysis for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 423: Africa Historic Review for Neurology Contract Research Organization by Study - Neuroscience Focused Study and Neurology Focused Study Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 424: Africa 16-Year Perspective for Neurology Contract Research Organization by Study - Percentage Breakdown of Value Sales for Neuroscience Focused Study and Neurology Focused Study for the Years 2014, 2025 & 2030
IV. COMPETITION
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.